Could a common asthma drug shield newborns from kidney damage?

NCT ID NCT05853601

Ongoing Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether the drug theophylline can prevent kidney injury in newborns who experienced oxygen deprivation at birth (HIE) and are receiving cooling therapy. Thirty infants will receive one or two doses of theophylline within 18 hours of birth. The main goal is to see if a larger trial is possible, not yet to prove the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: theophylline (a drug similar to caffeine, given intravenously)
What this could lead to: If this works, it could point toward a way to prevent kidney injury in thousands of at-risk newborns with HIE.
What could go wrong: This is a very early, small pilot study with only 30 infants. It is designed mainly to test feasibility and safety, not to prove the drug works. Theophylline can cause side effects like rapid heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

perinatal asphyxia acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY HIE

Contacts and locations

Locations

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.